FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899125006> ?p ?o ?g. }

• W2899125006 endingPage "817" @default.
• W2899125006 startingPage "807" @default.
• W2899125006 abstract "The majority of Merkel cell carcinoma, a highly aggressive neuroendocrine cancer of the skin, is associated with Merkel cell polyomavirus infection. Polyomavirus binding, internalization, and infection are mediated by glycosphingolipids. Besides receptor function, bioactive sphingolipids are increasingly recognized as potent regulators of several hallmarks of cancer. Merkel cell polyomavirus+ and Merkel cell polyomavirus– cells express serine palmitoyl transferase subunits and sphingosine kinase (SK) 1/2 mRNA. Induced expression of Merkel cell polyomavirus–large tumor antigen in human lung fibroblasts resulted in upregulation of SPTLC1-3 and SK 1/2 expression. Therefore, we exploited pharmacological inhibition of sphingolipid metabolism as an option to interfere with proliferation of Merkel cell polyomavirus+ Merkel cell carcinoma cell lines. We used myriocin (a serine palmitoyl transferase antagonist) and two SK inhibitors (SKI-II and ABC294640). In MKL-1 and WaGa cells myriocin decreased cellular ceramide, sphingomyelin, and sphingosine-1-phosphate content. SKI-II increased ceramide species but decreased sphingomyelin and sphingosine-1-phosphate concentrations. Aberrant sphingolipid homeostasis was associated with reduced cell viability, increased necrosis, procaspase-3 and PARP processing, caspase-3 activity, and decreased AKTS473 phosphorylation. Myriocin and SKI-II decreased tumor size and Ki-67 staining of xenografted MKL-1 and WaGa tumors on the chorioallantoic membrane. Our data suggest that pharmacological inhibition of sphingolipid synthesis could represent a potential therapeutic approach in Merkel cell carcinoma. The majority of Merkel cell carcinoma, a highly aggressive neuroendocrine cancer of the skin, is associated with Merkel cell polyomavirus infection. Polyomavirus binding, internalization, and infection are mediated by glycosphingolipids. Besides receptor function, bioactive sphingolipids are increasingly recognized as potent regulators of several hallmarks of cancer. Merkel cell polyomavirus+ and Merkel cell polyomavirus– cells express serine palmitoyl transferase subunits and sphingosine kinase (SK) 1/2 mRNA. Induced expression of Merkel cell polyomavirus–large tumor antigen in human lung fibroblasts resulted in upregulation of SPTLC1-3 and SK 1/2 expression. Therefore, we exploited pharmacological inhibition of sphingolipid metabolism as an option to interfere with proliferation of Merkel cell polyomavirus+ Merkel cell carcinoma cell lines. We used myriocin (a serine palmitoyl transferase antagonist) and two SK inhibitors (SKI-II and ABC294640). In MKL-1 and WaGa cells myriocin decreased cellular ceramide, sphingomyelin, and sphingosine-1-phosphate content. SKI-II increased ceramide species but decreased sphingomyelin and sphingosine-1-phosphate concentrations. Aberrant sphingolipid homeostasis was associated with reduced cell viability, increased necrosis, procaspase-3 and PARP processing, caspase-3 activity, and decreased AKTS473 phosphorylation. Myriocin and SKI-II decreased tumor size and Ki-67 staining of xenografted MKL-1 and WaGa tumors on the chorioallantoic membrane. Our data suggest that pharmacological inhibition of sphingolipid synthesis could represent a potential therapeutic approach in Merkel cell carcinoma." @default.
• W2899125006 created "2018-11-09" @default.
• W2899125006 creator A5003322799 @default.
• W2899125006 creator A5016329469 @default.
• W2899125006 creator A5020023127 @default.
• W2899125006 creator A5022851559 @default.
• W2899125006 creator A5035832516 @default.
• W2899125006 creator A5055552639 @default.
• W2899125006 creator A5058791594 @default.
• W2899125006 creator A5063696587 @default.
• W2899125006 creator A5065568964 @default.
• W2899125006 creator A5067045121 @default.
• W2899125006 creator A5074206887 @default.
• W2899125006 creator A5074497583 @default.
• W2899125006 creator A5078911757 @default.
• W2899125006 creator A5090515176 @default.
• W2899125006 date "2019-04-01" @default.
• W2899125006 modified "2023-10-17" @default.
• W2899125006 title "Pharmacological Inhibition of Serine Palmitoyl Transferase and Sphingosine Kinase-1/-2 Inhibits Merkel Cell Carcinoma Cell Proliferation" @default.
• W2899125006 cites W1256777839 @default.
• W2899125006 cites W1888129961 @default.
• W2899125006 cites W1909452331 @default.
• W2899125006 cites W1966452335 @default.
• W2899125006 cites W1966911854 @default.
• W2899125006 cites W1970096881 @default.
• W2899125006 cites W1973704821 @default.
• W2899125006 cites W1983079076 @default.
• W2899125006 cites W1993463575 @default.
• W2899125006 cites W1996386552 @default.
• W2899125006 cites W2000678775 @default.
• W2899125006 cites W2009021880 @default.
• W2899125006 cites W2020541351 @default.
• W2899125006 cites W2020730385 @default.
• W2899125006 cites W2023595695 @default.
• W2899125006 cites W2027432294 @default.
• W2899125006 cites W2039363965 @default.
• W2899125006 cites W2047082367 @default.
• W2899125006 cites W2051924129 @default.
• W2899125006 cites W2052840947 @default.
• W2899125006 cites W2053310582 @default.
• W2899125006 cites W2055376217 @default.
• W2899125006 cites W2055914778 @default.
• W2899125006 cites W2077154885 @default.
• W2899125006 cites W2079149661 @default.
• W2899125006 cites W2079770872 @default.
• W2899125006 cites W2091041966 @default.
• W2899125006 cites W2094107077 @default.
• W2899125006 cites W2097202436 @default.
• W2899125006 cites W2104174436 @default.
• W2899125006 cites W2112366257 @default.
• W2899125006 cites W2122164502 @default.
• W2899125006 cites W2138505582 @default.
• W2899125006 cites W2138520528 @default.
• W2899125006 cites W2147245292 @default.
• W2899125006 cites W2148322981 @default.
• W2899125006 cites W2160466693 @default.
• W2899125006 cites W2163527772 @default.
• W2899125006 cites W2171480930 @default.
• W2899125006 cites W2184261862 @default.
• W2899125006 cites W2547701444 @default.
• W2899125006 cites W2553481386 @default.
• W2899125006 cites W2563456874 @default.
• W2899125006 cites W2594376261 @default.
• W2899125006 cites W2595196370 @default.
• W2899125006 cites W2602454999 @default.
• W2899125006 cites W2602946883 @default.
• W2899125006 cites W2606476433 @default.
• W2899125006 cites W2750984295 @default.
• W2899125006 cites W2765847865 @default.
• W2899125006 cites W2768617092 @default.
• W2899125006 cites W2769383666 @default.
• W2899125006 cites W2792068190 @default.
• W2899125006 cites W2793389498 @default.
• W2899125006 doi "https://doi.org/10.1016/j.jid.2018.10.024" @default.
• W2899125006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30399362" @default.
• W2899125006 hasPublicationYear "2019" @default.
• W2899125006 type Work @default.
• W2899125006 sameAs 2899125006 @default.
• W2899125006 citedByCount "15" @default.
• W2899125006 countsByYear W28991250062019 @default.
• W2899125006 countsByYear W28991250062020 @default.
• W2899125006 countsByYear W28991250062021 @default.
• W2899125006 countsByYear W28991250062022 @default.
• W2899125006 crossrefType "journal-article" @default.
• W2899125006 hasAuthorship W2899125006A5003322799 @default.
• W2899125006 hasAuthorship W2899125006A5016329469 @default.
• W2899125006 hasAuthorship W2899125006A5020023127 @default.
• W2899125006 hasAuthorship W2899125006A5022851559 @default.
• W2899125006 hasAuthorship W2899125006A5035832516 @default.
• W2899125006 hasAuthorship W2899125006A5055552639 @default.
• W2899125006 hasAuthorship W2899125006A5058791594 @default.
• W2899125006 hasAuthorship W2899125006A5063696587 @default.
• W2899125006 hasAuthorship W2899125006A5065568964 @default.
• W2899125006 hasAuthorship W2899125006A5067045121 @default.
• W2899125006 hasAuthorship W2899125006A5074206887 @default.
• W2899125006 hasAuthorship W2899125006A5074497583 @default.
• W2899125006 hasAuthorship W2899125006A5078911757 @default.
• W2899125006 hasAuthorship W2899125006A5090515176 @default.

• next